MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Pentadeca Arginate Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Pentadeca Arginate (PDA) is a stabilized arginate-salt version of BPC-157, a synthetic 15-amino-acid body-protection-compound peptide derived from human gastric juice (PMID 27847966, PMID 21030672). It is promoted for tendon, ligament, muscle, and gut healing. Mechanistically BPC-157 up-regulates and activates the VEGFR2-Akt-eNOS angiogenic pathway, modulates nitric-oxide signaling, and drives fibroblast migration via FAK-paxillin, accelerating tissue repair in rodent models. Typical extrapolated dosing is 250-500 mcg subcutaneously once or twice daily, up to about 1,000 mcg/day, for 4-8 weeks. Plasma half-life is under 30 minutes in animals, yet tissue effects persist (a PK-PD disconnect). Critically, no peer-reviewed study has evaluated PDA as a distinct molecule, and human BPC-157 data are limited to a few small uncontrolled case series. Neither compound is FDA- or EMA-approved; BPC-157 was placed on the FDA's Category 2 bulk-substance list and is WADA-prohibited. Sold for research and educational use only.
Reconstitute: Add 2 mL bacteriostatic water → 5 mg/mL concentration.
Typical dose: 250-500 mcg 1-2x/day SC (up to ~1000 mcg/day)
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 0.0500 mg (50 mcg) on a U-100 insulin syringe.
Storage: Lyophilized powder stored frozen at −20 °C and protected from light; reconstituted solution refrigerated at 2-8 °C and used within roughly 30 days. Avoid repeated freeze-thaw cycles of the reconstituted solution and do not shake.
Half-life: No PDA data published. BPC-157 plasma half-life is under 30 minutes in animals (~15 min IV in rats), with IM bioavailability ~14-19% in rats; tissue/healing effects outlast plasma levels.
Route: Subcutaneous injection (modeled here); oral/capsule forms are also marketed for gut goals. PDA-specific human pharmacokinetics have not been characterized.
Status: Not FDA- or EMA-approved; BPC-157 placed in FDA Category 2 bulk drug substances; WADA-prohibited; research and educational use only, not medical advice.
About Pentadeca Arginate
Pentadeca Arginate (PDA) is an arginate-salt analog of the regenerative pentadecapeptide BPC-157, supplied as a lyophilized powder for subcutaneous injection. Unlike many compounds catalogued here, an injectable subcutaneous route is genuinely used for BPC-157/PDA in research and anecdotal practice, so the reconstitution figures below map onto how the injectable form is actually handled — but be clear that every efficacy and pharmacokinetic figure is borrowed from BPC-157 animal studies, because PDA itself has never been studied as a separate molecule [1][7].\n\nThe Pentadeca Arginate dosage modeled here follows published BPC-157 research ranges: a common starting point is 250 mcg once daily, with a standard window of 250-500 mcg injected once or twice daily, and an upper acute-phase ceiling near 1,000 mcg/day, typically run for 4-8 weeks [5][7]. Because BPC-157's plasma half-life is very short (under 30 minutes in animals) while its tissue effects persist, protocols tend to favor frequent, smaller doses rather than large infrequent ones [2].\n\nReconstituting a 10 mg vial with 2 mL of bacteriostatic water yields a 5 mg/mL solution (50 mcg per insulin-syringe unit), so 250 mcg measures 5 units and 500 mcg measures 10 units on a U-100 syringe — clean, measurable marks. Some users instead take oral or capsule BPC-157/PDA for gut-directed goals; those routes are not modeled by these subcutaneous figures.\n\nFrequency: Inject once daily subcutaneously, or split into two daily injections (AM/PM) during an acute repair phase. Pentadeca Arginate is not FDA- or EMA-approved and is presented here for educational purposes only.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2 mL of bacteriostatic water into a sterile syringe; this yields a 5 mg/mL solution from a 10 mg vial (50 mcg per insulin-syringe unit).
Inject the water slowly down the inner wall of the vial; do not spray directly onto the lyophilized powder and avoid foaming.
Gently swirl or roll the vial until the solution is completely clear; do not shake, as vigorous agitation can fragment the peptide.
Load a U-100 insulin syringe to the units for your dose: 250 mcg = 5 units, 500 mcg = 10 units, 1,000 mcg = 20 units.
Swab the site (the abdomen, or near the area of interest, is common in BPC-157 protocols), inject subcutaneously, rotate sites, and return the vial to the refrigerator (use within ~30 days).
Interactive Pentadeca Arginate Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 2mL water yields 5.00 mg/mL. To evaluate a 250mcg dose, pull to 5.0 units (5 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Weeks 1-2 — initiation, once daily | 250 mcg | 5 units (0.05 mL) |
| Weeks 2-6 — standard repair, once daily | 500 mcg | 10 units (0.10 mL) |
| Acute upper range — once daily or split AM/PM (~1,000 mcg/day) | 1000 mcg (1 mg) | 20 units (0.20 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (Pentadeca Arginate, 10 mg each):
- check8 weeks at 500 mcg/day ≈ 28 mg ≈ 3 vials
- check12 weeks at 500 mcg/day ≈ 42 mg ≈ 5 vials
- check16 weeks at 1,000 mcg/day (acute upper range) ≈ 112 mg ≈ 12 vials
Insulin Syringes (U-100):
- checkOnce-daily dosing: 7 syringes/week — 8 weeks ≈ 56, 12 weeks ≈ 84, 16 weeks ≈ 112
- checkTwice-daily acute dosing: 14 syringes/week — roughly doubles the counts above
- checkOrder a few spares for priming and dropped needles
Bacteriostatic Water (30 mL bottles): Use 2 mL per 10 mg vial for reconstitution.
- check8 weeks (≈3 vials) ≈ 6 mL
- check12 weeks (≈5 vials) ≈ 10 mL
- check16 weeks (≈12 vials, acute range) ≈ 24 mL — one 30 mL bottle covers a full course
Alcohol Swabs:
- check1-2 swabs per injection (vial septum + injection site)
- check8 weeks once daily ≈ 56-112 swabs; 12 weeks ≈ 84-168
- check16 weeks twice daily ≈ 224+ swabs; keep extras for re-swabbing the multi-use vial
Mechanism of Action (MOA)
Pentadeca Arginate is the same 15-residue sequence as BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) paired with an arginine counter-ion instead of acetate. BPC-157 is a "stable gastric pentadecapeptide," a synthetic fragment of a body-protection compound isolated from human gastric juice that is unusually resistant to acid and enzymatic degradation, remaining intact in gastric juice for more than 24 hours [1]. Vendors market the arginate salt as more stable and better absorbed; this is a formulation claim, not a peer-reviewed finding, and no published study has characterized PDA as a separate molecule, so its mechanism is assumed to be identical to BPC-157 [7].\n\nThe best-characterized mechanism is pro-angiogenic. BPC-157 up-regulates vascular endothelial growth factor receptor 2 (VEGFR2), promotes its internalization, and activates the downstream VEGFR2-Akt-eNOS cascade, increasing endothelial cell proliferation, migration, tube formation, and new blood-vessel growth in ischemic tissue [3]. This raises nitric-oxide availability and interacts bidirectionally with the NO system: BPC-157 can override the effects of NOS blockade (L-NAME) and of NO excess (L-arginine), behaving as a homeostatic modulator rather than a one-directional agonist [1]. In tendon, BPC-157 accelerates the ex vivo outgrowth of fibroblasts from explants, improves cell survival under oxidative stress, and dose-dependently increases fibroblast migration through activation of the FAK-paxillin signaling pathway [4]. In vivo, it speeds healing of transected rat Achilles tendon, improving biomechanical strength, collagen organization, and functional recovery [5]. Comparable effects are reported for muscle, ligament, bone-to-tendon junctions, nerve, and gastrointestinal mucosa, alongside cytoprotective and anti-inflammatory actions linked to the gut-brain axis [1].\n\nPharmacokinetics come entirely from BPC-157 studies. After injection the plasma elimination half-life is very short — about 15 minutes IV in rats and under 30 minutes across IV and intramuscular dosing in rats and dogs — and intramuscular bioavailability is roughly 14-19% in rats and 45-51% in dogs [2]. The peptide is rapidly degraded into small fragments and individual amino acids (notably proline) that enter normal amino-acid metabolism, and is cleared mainly via urine and bile [2]. This short half-life paired with durable tissue effects is the often-cited "PK-PD disconnect," and it is why protocols favor frequent, smaller subcutaneous doses, sometimes injected near the area of interest, rather than large infrequent ones [2][5].\n\nHuman evidence is minimal. Only a handful of small, uncontrolled human reports exist (knee pain, interstitial cystitis, an intravenous safety pair), and a Croatian program tested BPC-157 (PL-14736) for inflammatory bowel disease, but no adequately powered randomized trial has been published [6][7]. Because PDA has never been formally studied, all of the above is extrapolation, and the subcutaneous reconstitution scheme on this page is an educational measurement reference, not a validated clinical protocol [7][8].
Clinical Trial Efficacy Highlights
- starHsieh and colleagues (2017, J Mol Med) showed that BPC-157 is pro-angiogenic: it up-regulated VEGFR2, promoted its internalization, and time-dependently activated the VEGFR2-Akt-eNOS pathway in vascular endothelial cells, increasing vessel density in chick chorioallantoic membrane and tube-formation assays and accelerating blood-flow recovery in ischemic rat hindlimb, with effects blocked by the endocytosis inhibitor dynasore [3].
- starChang and colleagues (2011, J Appl Physiol) demonstrated that BPC-157 accelerated the ex vivo outgrowth of fibroblasts from rat Achilles tendon explants, improved tendon-cell survival under H2O2 oxidative stress, and dose-dependently increased fibroblast migration, effects attributed to increased phosphorylation of FAK and paxillin without changes in total protein [4].
- starStaresinic and colleagues (2003, J Orthop Res) reported that BPC-157 accelerated healing of surgically transected rat Achilles tendon, improving load-bearing capacity, elasticity, collagen formation, functional recovery, and reducing tendon defect size by day 14, while also stimulating tendocyte growth in vitro [5].
- starSikiric and colleagues' comprehensive review (Gut Liver 2020) summarizes BPC-157's cytoprotective and organoprotective actions across the gastrointestinal tract and other organs, its central interaction with the nitric-oxide system, resistance to degradation in human gastric juice for over 24 hours, and a wide safety margin in which an LD-1 was not achieved and no adverse effects were reported in clinical testing [1].
- starHe and colleagues (2022, Front Pharmacol) characterized BPC-157 pharmacokinetics using radiolabeled peptide, finding an elimination half-life under 30 minutes (about 15 min IV in rats, ~5 min IV in dogs), intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs, rapid degradation to amino acids, and excretion mainly via urine and bile [2].
- starKlicek and colleagues (2008, J Pharmacol Sci) noted that BPC-157, then in clinical trials for inflammatory bowel disease as PL-14736, healed colocutaneous fistulas in rats via the nitric-oxide system, illustrating the gut-healing rationale behind oral BPC-157/PDA use, though full human IBD trial outcomes were never published as a standalone clinical paper [6].
- starMcGuire and colleagues' 2025 narrative review (Curr Rev Musculoskelet Med) concludes that despite broad preclinical support, human data are limited to roughly three small uncontrolled reports, that BPC-157 should be considered investigational and used with caution, and — importantly for this entry — makes no mention of pentadeca arginate, underscoring that PDA itself has no published clinical or pharmacologic evidence base [7].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningInjection-site reactions (transient redness, stinging, bruising, or itching) are the most commonly reported subcutaneous effect; rotating sites and using sterile technique reduces irritation.
- warningHuman safety data are minimal: the entire human BPC-157 literature is a few small, uncontrolled case series, and Pentadeca Arginate has never been formally studied, so its true side-effect profile in humans is unknown [7].
- warningBecause PDA is sold as a research chemical, product identity, purity, dose accuracy, and the actual salt/counter-ion are not independently verified; contamination or mislabeling is a real-world risk with unregulated peptides.
- warningBPC-157 is strongly pro-angiogenic, which raises a theoretical concern that promoting new blood-vessel growth could be undesirable in the setting of malignancy or proliferative retinopathy; this has not been characterized in controlled human studies [3].
- warningAnecdotal reports describe systemic effects such as lightheadedness, fatigue, headache, transient blood-pressure changes, and gastrointestinal upset; these are not derived from controlled trials and should be interpreted cautiously [7].
- warningBPC-157 (and by extension PDA) is on the World Anti-Doping Agency Prohibited List under non-approved substances, so use carries sanction risk for tested athletes [7].
- warningRegulatory/research status: neither BPC-157 nor Pentadeca Arginate is approved by the FDA or EMA; BPC-157 was placed in the FDA's Category 2 of bulk drug substances that may present significant safety risks, restricting its use in compounding. PDA is offered for research and educational use only and is not a medicine [7][8].
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Pentadeca Arginate dosage?expand_more
There is no validated, PDA-specific dose, because Pentadeca Arginate has never been studied as a distinct molecule. The figures used in practice are extrapolated from BPC-157 protocols: roughly 250-500 mcg injected subcutaneously once or twice daily, with some users reaching about 1,000 mcg/day during an acute repair phase, typically run for 4-8 weeks. A common approach is to start at 250 mcg once daily (5 units of a 5 mg/mL solution) and titrate to 500 mcg as tolerated. These are educational reference figures, not a prescribed dose.
Is Pentadeca Arginate FDA approved?expand_more
No. Neither Pentadeca Arginate nor its parent peptide BPC-157 is approved by the FDA or EMA for any indication. The FDA placed BPC-157 in Category 2 of its bulk drug substances list, citing significant safety concerns, which restricts its use in compounded medications, and PDA inherits that status as a variant of the same pentadecapeptide. It is also prohibited by the World Anti-Doping Agency. Pentadeca Arginate is sold strictly for research and educational use, and this page is not medical advice.
What is the half-life of Pentadeca Arginate?expand_more
No pharmacokinetic study has been published for Pentadeca Arginate specifically. For BPC-157, the plasma elimination half-life is very short — about 15 minutes after intravenous dosing in rats and under 30 minutes across routes in rats and dogs — with intramuscular bioavailability around 14-19% in rats. Notably, BPC-157's tissue and healing effects outlast its plasma presence (a pharmacokinetic-pharmacodynamic disconnect), which is why protocols use frequent, smaller subcutaneous doses rather than large infrequent ones.
How do you reconstitute Pentadeca Arginate?expand_more
For the educational subcutaneous model on this site, a 10 mg vial is reconstituted with 2 mL of bacteriostatic water to give a 5 mg/mL solution, which works out to 50 mcg per insulin-syringe unit. Draw the water slowly down the inner wall of the vial, swirl gently until clear (do not shake), and refrigerate. At that concentration 250 mcg measures 5 units, 500 mcg measures 10 units, and 1,000 mcg measures 20 units on a U-100 insulin syringe. Use the reconstituted solution within about 30 days.
Can Pentadeca Arginate be stacked with other peptides?expand_more
Anecdotally, BPC-157/PDA is often combined with TB-500 (thymosin beta-4 fragment), GHK-Cu, or growth-hormone secretagogues in recovery-oriented stacks, but there are no controlled human data supporting any of these combinations, and none have been studied for PDA. Because PDA itself is unstudied and sold as a research chemical, treat any stack as experimental: product purity, identity, and interactions are not verified. This is informational only and not a recommendation to use or combine these compounds.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Pentadeca Arginate, plus the universal dosing calculator.
Academic References & Study Citations
Sikirić P, Hahm KB, Blagaić AB, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut Liver. 2020;14(2):153-167. View Scientific Paper →
He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. View Scientific Paper →
Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. View Scientific Paper →
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. View Scientific Paper →
Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. View Scientific Paper →
Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci. 2008;108(1):7-17. View Scientific Paper →
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. View Scientific Paper →
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 bulk drug substances; includes BPC-157). FDA Human Drug Compounding. View Scientific Paper →